Can a Patient with Metastatic Breast Cancer Stop HER2 Treatment After Years of Disease Control – SABCS
Heather Parsons / fredhutch.org

Can a Patient with Metastatic Breast Cancer Stop HER2 Treatment After Years of Disease Control – SABCS

San Antonio Breast Cancer Symposium (SABCS) shared on X:

“The phase II STOP-HER2 trial followed patients with HER2-positive metastatic breast cancer who stopped trastuzumab after a sustained response.

Heather Parsons presents December 11 at SABCS 2026.

Learn more.

SABCS

About SABCS 2026

The San Antonio Breast Cancer Symposium (SABCS 2026) is the world’s largest scientific meeting dedicated to breast cancer research and clinical care, co-organized by UT Health San Antonio and the American Association for Cancer Research (AACR).

Each December, more than 11,000 physicians, researchers, clinicians, and patient advocates from over 100 countries gather in San Antonio to present groundbreaking research, exchange ideas, and advance breast cancer care worldwide.

  • Date: December 8-11, 2026
  • Location: Henry B. Gonzalez Convention Center, San Antonio, Texas, USA
  • Format: Hybrid (in-person and virtual attendance), with recorded sessions remaining available on demand through March 31, 2027.

The 2026 program centers on several major scientific and clinical areas, led by biomarker-guided and targeted therapies, featuring updates on precision therapy in metastatic breast cancer, long-term CDK4/6 inhibitor data (such as ribociclib/Kisqali), radioligand therapies, and managing novel treatment-related toxicities.

Alongside targeted treatments, liquid biopsy and ctDNA take a prominent role through the clinical application of circulating tumor DNA and blood-based assays for minimal residual disease monitoring and treatment adaptation.

Artificial intelligence in oncology is also heavily featured through dedicated workshops and sessions on AI-driven pathology advancements, preventive risk assessment, and clinical decision-making tools.

In addition, the symposium highlights cancer prevention vaccines and immunotherapy, exploring emerging vaccine strategies that harness immunity for breast cancer prevention and interception, as well as metabolism, lifestyle, and supportive care, with special sessions examining the intersection of modern weight-loss medications (GLP-1 agonists) and breast cancer alongside integrating lifestyle medicine into survivorship and care.

Register for SABCS 2026.“

You can also read:

SABCS 2026